The London Life Sciences and Technology team advised Forbion (via its new BioEconomy Fund) and FMC Ventures on their investment in the oversubscribed $14 million Series A funding round for SOLASTA Bio.
Established in 2021, Glasgow-based SOLASTA Bio has developed the world's first technology platform for creating insect control agents that are nature-inspired rather than selected from a synthetic chemistry library. The funding will accelerate the development of the company’s unique peptide-based, nature-inspired bioinsecticides – the first of their kind to be developed worldwide.
Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing €3.2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address ‘planetary health’ challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies.
FMC Ventures is the corporate venture capital arm of FMC Corporation, a global agricultural sciences company dedicated to helping growers produce food, feed, fibre and fuel for an expanding world population. FMC Ventures invests globally in early-stage startup companies developing cutting-edge technologies that could reshape the future of agriculture. With a focus on innovations such as artificial intelligence, genomics, robotics, biologicals and agri-fintech, FMC Ventures identifies and supports startups that can deliver profitability for growers and a more sustainable future.
The Goodwin team was led by Graham Defries, Kenny Walker-Durrant, Tim Worden, Matthew Shelley, Lucy Sharples and Sonja Jounus.
For more details on the round, please see here.